Embolization Products Market: By Product Type (embolization Coils, Microspheres or Microbeads, Catheters), By Embolization Type (Arterial Embolization, Chemoembolization, Radioembolization), By Therapeutic Condition (Liver Cancer, Kidney Cancer, Neuroendocrine Tumours, Cardiovascular Diseases, Uterine Fibroids, Aneurysms, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Others), and Geography

Embolization Products Market size was valued at USD 834.70 million in 2021 and it is projected to reach USD 1345.28 million by 2028 growing at a CAGR of 5.2% from 2022 to 2028 owing to the rising adoption of advanced technologies and advantages such as faster recovery time, minimal risk of infection, no scarring, minimally invasive, and high success rates when compared to that of other procedures and no need of general anesthetic usage are the important factors drives the growth of the market. However, risk of emboli reaching healthy tissue potentially causing gastric, stomach or duodenal ulcers hampers the growth of the market. Global embolization products market report gives comprehensive outlook on embolization products across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report on global market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, embolization type, therapeutic condition, end user, and region. This report studies global embolization products market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global embolization products market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition.Global embolization products market is surging owing to launch of innovative products in different markets to expand the portfolio and strengthen their position in the market. Key Developments: In January 2018, Cerenovus, part of the Johnson & Johnson Medical Devices Companies, has announced the launch of the Galaxy G3 mini coil, its smallest and softest embolic finishing coil, for use in the endovascular treatment of cerebral aneurysms and haemorrhagic stroke. In March, 2018, BALT USA, LLC announced it has received 510(k) clearance for the Optima Coil System and completion of first clinical cases in the United States.